CMS didn’t reject ‘our approach’ to ACA, argues Idaho’s governor

When CMS told Idaho it couldn’t move ahead with plans to allow health insurers to offer coverage which doesn’t comply with the Affordable Care Act (ACA), Idaho Gov. Butch Otter didn’t see it as a rejection but rather the start of a negotiation.

Otter had proposed allowing “state-based plans” which brought back elements of pre-ACA individual market insurance design, like charging more or denying coverage based on pre-existing conditions and placing lifetime or annual caps on benefits. One insurer, Blue Cross of Idaho, was already set to offer the plans at less than half the monthly premium cost of a similar ACA exchange plan. But CMS Administrator Seema Verma, MPH, said the policy would be a failure to “substantially” uphold the law.

That’s the key word Otter and lawyers for Blue Cross of Idaho—what does “substantially” mean?

The argument obtained by the Idaho Statesman from attorney Anthony Shelley, outside counsel to Blue Cross of Idaho, is Congress meant to give “leeway for a state to decide sometimes not to enforce” the ACA, such as how certain “grandmothered” pre-ACA plans have been allowed to continue.

The almost-apologetic tone of the CMS letter, which said it “is certainly not our preference” to take over enforcement of the ACA from a state, did encourage Idaho to continue discussing options with federal agencies to offer insurance which it determines to comply with the law.

“We consider the letter an invitation from CMS to continue discussing the specifics of what can and cannot be included in state-based plans,” Otter said in a statement. “We will consider all possible options and then continue discussions with CMS and HHS on how best to achieve our shared goals of reducing the costs of coverage and stabilizing our health insurance market.”

Read more at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.